Cancer News and Research

Latest Cancer News and Research

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

Eli Lilly and Company today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera. In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled that Lilly's '590 patent, or method-of-use patent, for Strattera is invalid. The patent had been set to expire in May of 2017.

13 Aug 2010

DNA repair genes in melanoma tumours repair associated with poor response to chemotherapy: Research

A Link between the level of active DNA repair genes in melanoma tumours and the effectiveness of chemotherapy for skin cancer patients has been established for the first time by a team of scientists.The study, part-funded by Cancer Research UK and published in Clinical Cancer Research today (Friday), found that higher levels of DNA repair genes in melanoma tumours were associated with a poorer response to chemotherapy.

13 Aug 2010

Hana Biosciences second-quarter net loss decreases to $6.3 million

Hana Biosciences Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and six months ended June 30, 2010, and provided a corporate update.

13 Aug 2010

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.

13 Aug 2010

New multidisciplinary approach to glioblastoma multiforme treatment offers extended survival rates

The Hospital Universitario Donostia (at the city of Donostia-San Sebasti-n in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicol-s Sampr-n, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.

13 Aug 2010

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

In a move likely to secure its place as a leading provider of medical radiation countermeasures, Humanetics Corporation today announced that it has secured exclusive worldwide licenses to two new treatments that provide short and long-term post-exposure protection from ionizing radiation acquired during a terrorist act, nuclear or radiological attack or accident, as part of cancer radiotherapy or even during routine diagnostic CT scans.

13 Aug 2010

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Epitomics, Inc. today announced that it has spun-out to its shareholders a new biotechnology company called Apexigen, Inc., which will focus on the development and commercialization of humanized monoclonal antibodies for treatment of cancer and immuno-disorders.

13 Aug 2010

NAC to deliver education program on asthma management for youth

As children with asthma head back to school this fall, the National Asthma Campaign Foundation (NAC) is partnering with Respiratory Health Association of Metropolitan Chicago (RHAMC) to deliver Fight Asthma Now (FAN), an asthma education program that teaches youth to control and manage their asthma.

13 Aug 2010

Guided Therapeutics second-quarter service revenue increases to $0.8 million

Guided Therapeutics, Inc. today announced its operating results for the second quarter and first six months of 2010.

13 Aug 2010

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.

13 Aug 2010

BioSante second-quarter net loss increases to $10.8 million

BioSante Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010.

13 Aug 2010

CPF urges people to consider clinical trials for pulmonary fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is urging the more than 128,000 people known to suffer from the deadly lung disease, pulmonary fibrosis (PF), to consider clinical trials, including two new ones funded by the National Institutes of Health (NIH). Clinical trials of potential drug therapies are critical to the discovery of treatments for any disease and for a disease like PF that claims as many lives each year as breast cancer with virtually no survivors, they are the likely path to answers and saved lives.

13 Aug 2010

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Study finds Olaparib can reduce tumor size in ovarian cancer women

Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.

13 Aug 2010

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

Tracking heart rate can provide important marker of health issues: Research

An elevated resting heart rate that develops or persists during follow-up is associated with a significantly increased risk of death, whether from heart disease or other causes, researchers from the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center found studying outcomes in more than 9,000 patients.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

RPA70 associated with SUMO-specific protease facilitates DNA repair: Research

A team of investigators led by a physician-scientist at The University of Texas MD Anderson Cancer Center has shown for the first time that the small protein SUMO can team up with the replication protein A (RPA) complex to facilitate DNA repair. The study is published in the Aug. 13 edition of the journal Molecular Cell.

13 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

Cancer News and Research

Latest Cancer News and Research

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

DNA repair genes in melanoma tumours repair associated with poor response to chemotherapy: Research

Hana Biosciences second-quarter net loss decreases to $6.3 million

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

New multidisciplinary approach to glioblastoma multiforme treatment offers extended survival rates

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

NAC to deliver education program on asthma management for youth

Guided Therapeutics second-quarter service revenue increases to $0.8 million

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

BioSante second-quarter net loss increases to $10.8 million

CPF urges people to consider clinical trials for pulmonary fibrosis

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

Study finds Olaparib can reduce tumor size in ovarian cancer women

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Tracking heart rate can provide important marker of health issues: Research

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

RPA70 associated with SUMO-specific protease facilitates DNA repair: Research

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Industry Focus eBook: Oncology eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook: Oncology eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in